In September 2017 it was announced that Minnesota based Bio-Techne Corporation (NASDAQ: TECH) had acquired Trevigen Inc. in an all-cash tranactions. The two firms have had a long standing working relationship such that their products are complementary and the integration of their efforts are judged likely to make it easier to reach customers interested in products better to understand cell behavior and genotoxic events on cells. Having tools to study DNA damage and the apoptotic cell process is an important aspect of understanding drug action. As more drug testing is being conducted on physiologically more appropriate cell models, including 3D cell cultures, having membrane extracts products to support the robust growth of such cells, such as the Cultrex product line, makes these products an important addition to the Bio-Techne product. Trevigen Inc has been focused on developing products and technology for cancer research that emphasizes apoptosis, DNA damage/repair, and cancerous cell behavior. The firm'sTrevigen Cell Assays (TCA) component undetook contract research work for the pharmaceutical, biotechnology, government and academic research markets. With the increasing attention being placed on cell death and its role in cancer research, TCA specialized in designing and conducting assays for lead compound and genotoxic screening based on DNA damage and cancer cell function and behavior, including angiogenesis, cell invasion and tumor formation. Trevigen also provided the reagents and biotechnology equipment to those small or individual facilities that are taking an active role in studying DNA damage, cell death, and cancer cell behavior.
